Technology | Heart Valve Technology | July 18, 2018

Abbott Receives FDA Approval for Third-Generation MitraClip Device

Third-generation transcatheter valve repair device designed to allow doctors to treat more types of cases and anatomies

Abbott Receives FDA Approval for Third-Generation MitraClip Device

July 18, 2018 — Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for a next-generation version of its MitraClip heart valve repair device used to repair a leaky mitral valve without open-heart surgery. The transcatheter clip-based therapy, now on a third generation of product innovations, has been used to treat more than 65,000 patients worldwide over the last 10 years.

The next-generation MitraClip system provides cardiologists with advanced steering, navigation and positioning capabilities for the clip, making it easier to use in difficult anatomies. The enhanced system is designed to allow for more precise placement during deployment, resulting in more predictable procedures. It additionally offers a second clip size with longer arms that expands the reach of the clip-based device. The additional clip size is designed to help doctors treat patients who have more complex anatomies when repairing the mitral valve.

Abbott received CE Mark for the next-generation device earlier this year, allowing for sale of the devices in the European Union and other countries that recognize this regulatory designation.

"Physicians rely on MitraClip as an alternative to surgery for patients who aren't surgical candidates and may need treatment to relieve their symptoms or to survive," said Francesco Maisano, M.D., professor, UniversitätsSpital Zürich, Switzerland, who was an early implanter of MitraClip. "The enhanced MitraClip design allows for even more precise navigation, accuracy and stability during valve repairs, which may be important when treating people with more complex or advanced valve disease."

A leaking mitral valve, known as mitral regurgitation (MR), is a serious, progressive heart disease in which the flaps of the mitral valve do not close properly, allowing blood to flow backward into the heart. Incidence of mitral regurgitation increases with age, with nearly one in 10 people over the age of 75 having moderate to severe disease1. Before MitraClip, people who were not eligible for the standard-of-care surgery to treat their MR could only manage their symptoms with medications that do not stop the progression of the disease. Left untreated, MR leads to a variety of life-altering symptoms and severe complications, and may ultimately lead to heart failure and death.1,2,3.

MitraClip treats people with degenerative mitral regurgitation and is a therapy that is delivered via a catheter to the heart through a blood vessel in the leg. MR patients are often not eligible for the standard-of-care surgery because of advanced age, frailty, multiple comorbidities or other complicating factors and the therapy offers a minimally invasive alternative. Treatment with MitraClip provides almost immediate symptom relief and patients are released from the hospital on average after two days.

Abbott recently began enrollment in the MitraClip EXPAND clinical study, a prospective study evaluating the safety and performance of the new MitraClip system in a contemporary real-world setting. Saibal Kar, M.D., director of interventional cardiac research at the Smidt Heart Institute at Cedars-Sinai in Los Angeles, treated the first patient enrolled, and is the lead investigator of the study. EXPAND will enroll approximately 1,000 patients in more than 50 centers across the U.S. and Europe and interim results from the study are expected later this year.

MitraClip received initial CE Mark approval in Europe in 2008 and was approved by the FDA in 2013. By securing a portion of the leaflets of the mitral valve with an implanted clip, the heart can pump blood more efficiently throughout the body, thereby relieving the symptoms of severe MR and improving patient quality of life.4

For more information: www.vascular.abbott.us

Read the related article Treating Mitral Regurgitation in High Risk PatientsUsing the MitraClip — by Allen Atchley, M.D.

 

References

1. Healthline.com. Mitral Valve Disease. 2016. Accessed April 10, 2018.  

2. Patient Info. Mitral Regurgitation. 2017. Accessed April 10, 2018.  

3. National Heart, Lung and Blood Institute. What is Heart Valve Disease? 2015. Accessed April 10, 2018.   

4. http://eifu.abbottvascular.com/content/dam/av/eifu-us/EL2106481%20Rev.%20A%202016-04-28.pdf

 

Related MitraClip Content

Expanded MitraClip Registry Shows Continued Positive Results

VIDEO: Update of Mitral Valve Repair and Replacement Technologies

Canadian Cardiologist Publishes World-First Mitral Regurgitation Procedure

Related Content

TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...